Alexion Pharmaceuticals

Alexion (acquired by AstraZeneca) specialized in rare diseases, particularly complement-mediated disorders like paroxysmal nocturnal hemoglobinuria. The company's blockbuster drug Soliris was one of the most expensive medicines globally. Alexion demonstrated that ultra-rare disease drugs could be commercially successful despite small patient populations.